ClinicalTrials.gg
RecruitingNCT07298122CATCH MEUpdated Dec 23, 2025

Cardiac Assessment for Thrombus Detection in the Heart Using Advanced Imaging (MRI, CT) in ESUS With Left Ventricular Disease

An observational study in Cryptogenic Ischemic Stroke, sponsored by Niguarda Hospital. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Niguarda Hospital · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Ischemic Stroke with a site in Italy — 23 open to participants now, 29 under way, 2 of them phase 3. Ischemic Stroke · Italy.

Planned enrollment
25th of 30
125 · median 550
Started
2025
with 10 others
Observational
30 of 81
11 open now
Primary completion
2028-09
later than 21 of 28 live
Registered
79th of 81
by date
Lead sponsor
3 of 81
Niguarda Hospital

Among the 81 studies in Ischemic Stroke with a site in Italy, this one is the 25th largest by planned enrollment of the 30 observational ones that give a count, is one of 11 that started in 2025, is one of 30 observational ones, reaches primary completion later than 21 of the 28 other live ones, and was the 79th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

23 of the 81 studies in Ischemic Stroke with a site in Italy are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Ischemic Stroke with a site in Italy, or all of them as a file.
02

Study summary

The CATCH ME study is a prospective, multicenter, observational, no-profit study aimed at improving embolic risk stratification in patients with embolic stroke of undetermined source (ESUS), particularly in those with left ventricular disease (LVD). LVD is defined by a mildly to moderately reduced ejection fraction (30-49%), left ventricular wall motion abnormalities (hypo/akinesia), ventricular dilation, cardiomyopathies, and other related conditions. In these patients, the intermittent formation of intracardiac thrombi within the ventricle, often undetectable by standard diagnostic evaluation such as transthoracic echocardiography (TTE) alone, may serve as an unrecognized embolic source. However, in clinical practice, such patients are frequently discharged on antiplatelet therapy alone, without adequate thromboembolic risk stratification, thus leaving them at a high risk of ischemic recurrence. This study aims to assess the additional diagnostic value of advanced cardiac imaging - Cardiac Magnetic Resonance Imaging (CMRI) and/or Cardiac Computed Tomography (CCT) - in detecting intracardiac thrombi not identified by TTE in patients with ESUS and LVD.

Read the detailed description

ESUS is a subgroup of ischemic stroke characterized by several potential embolic sources and represents a significant challenge in clinical management. Among ESUS patients, those with LVD, defined as a mildly to moderately reduced ejection fraction (30-49%), left ventricular wall motion abnormalities (LVWMAs), ventricular dilation, cardiomyopathies, and other related conditions, constitute a high-risk subgroup for adverse outcomes. In this population, the underlying stroke mechanism could be the intermittent formation of intraventricular thrombi. Factors such as low cardiac output, dilated cardiac chambers, poor contractility, and endothelial dysfunction may activate Virchow's triad, thereby increasing the risk of thrombosis. The standard cardiac diagnostic approach for these patients typically includes TTE, which is often unable to detect small intracardiac thrombi, due to their transient nature or the limited sensitivity of TTE. This limitation may lead to a diagnostic gap, with the potential risk of not implementing adequate secondary prevention therapy. In fact, these patients are usually discharged with antiplatelet therapy, despite several studies showing a higher risk of stroke recurrence. Advanced cardiac imaging techniques, including CCT and CMRI, are increasingly being used in the diagnostic evaluation of ESUS patients. Studies have demonstrated their role in identifying significant vascular and cardiac abnormalities not otherwise detected by TTE, leading to a reclassification of the stroke etiology and a consequent reduction in the ESUS prevalence. Current AHA/ASA guidelines recommend the use of advanced cardiac imaging (CMRI and CCT) in selected ESUS cases to optimize preventive therapy and reduce the risk of recurrence (class 2b, level of evidence C). CMRI, in particular, is recommended when (1) there is suspicion of an intracardiac thrombus but TTE results are inconclusive, or (2) TTE is negative but there remains a clinical suspicion of a cardioembolic stroke etiology. Studies have shown that both CCT and CMRI allow for the detection of cardiac thrombi significantly more often than TTE in ESUS patients, especially those with markers of LVD. CMRI is considered the gold standard for non-invasive evaluation of the left ventricle and has the highest sensitivity in detecting ventricular thrombi. Despite the relatively widespread use of advanced cardiac imaging in selected ESUS cases, there is currently a lack of systematic data on its clinical utility in this specific population. This study aims to assess the role of advanced cardiac imaging (CMRI and/or CCT) in detecting intracardiac thrombi in ESUS patients with LVD compared to the use of TTE alone. This study intends to provide real-world evidence on the additional diagnostic value of advanced cardiac imaging, contributing to a better understanding of its utility in secondary stroke prevention.

The study will last for three years, with a recruitment period of two years and 1 year of follow-up. It will be conducted in three phases:

  1. Initial Screening Phase (Phase 1): Inclusion of all ESUS patients with acute ischemic stroke and LVD. Patients with thrombi detected via TTE will be classified as cardioembolic and excluded from the ESUS subgroup analysis, but included in the initial data collection phase to assess the prevalence of ventricular thrombi in this population.
  2. Imaging Phase (Phase 2): This phase will focus on the subgroup of patients classified as ESUS with LVD, where no thrombi were detected by TTE, and who will undergo advanced cardiac imaging (CMRI, CCT), as recommended by current guidelines, within 15 days from the index ischemic event.
  3. Follow-up (Phase 3): All recruited patients (both those classified as cardioembolic and ESUS) will be followed for a period of 24 months to monitor the occurrence of vascular events, recurrent ischemic stroke, hemorrhagic events, atrial fibrillation, mortality, and any therapeutic modifications.

The main goal is to evaluate the diagnostic effectiveness of advanced cardiac imaging (CMRI and/or CCT) in identifying intracardiac thrombi in ESUS patients with LVD who have negative TTE results (no thrombi). The study will also aim to determine the prevalence of intracardiac thrombi detected by TTE in all patients with ESUS and LVD. Additionally, it will assess the clinical and cardiac differences between patients based on whether thrombi are present and the method used for detecting them. The study will examine how the results from CMRI and/or CCT influence therapeutic decisions, such as the initiation of anticoagulant therapy when thrombi are found. Furthermore, the study will evaluate the risk of adverse events during follow-up, including recurrent strokes, coronary events, major bleeding episodes, and mortality.

03

Conditions studied

  • Cryptogenic Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged between 18 and 85 years, with an mRS score ≤ 4 and Ischemic stroke classified as ESUS according to standard criteria, with LVD (defined as moderately reduced ejection fraction 30-49%, presence of LC wall motion abnormalities, LV aneurysm, LV dilatation with or without spontaneous echo-contrast, non-compacted LV [with deep trabeculations or spongy LV], cardiomyopathies [severe restrictive cardiomyopathy, cardiac amyloidosis, hypertrophic cardiomyopathy]), in whom no intracardiac thrombi are identified on transthoracic echocardiogram and who are able to undergo advanced cardiac imaging (CMRI and/or CCT).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 85 years Modified Rankin Scale (mRS) score ≤ 4 Diagnosis of acute ischemic stroke (detected by CT or brain MRI) Diagnosis of ESUS according to standard criteria
  • Stroke detected by CT or MRI that is not lacunar. Lacunar is defined as a subcortical infarction (including pons and mesencephalon) in the distribution of the small penetrating cerebral arteries, with a maximum size ≤ 1.5 cm on CT or ≤ 2.0 cm on diffusion-weighted MRI images (\< 1.5 cm on T2-weighted MRI images). Excluded: multiple small deep infarcts, lateral bulb infarcts, cerebellar infarcts, patients with clinical lacunar stroke syndrome and no visible infarction on imaging.
  • Absence of extracranial or intracranial atherosclerosis causing ≥ 50% stenosis in the artery supplying the ischemic area. Vascular imaging of the extracranial and intracranial vessels is required using angiography, CT angiography (CTA), MR angiography (MRA), or color Doppler ultrasound, at the discretion of the treating physician and local principal investigator.
  • No major cardioembolic source identified, including permanent or paroxysmal atrial fibrillation (AF), sustained atrial flutter, intracardiac thrombus (*as specified above, these patients will be recruited in phase 1 of the study only if an isolated ventricular thrombus is found without other major cardiac causes), mechanical heart valve prosthesis, atrial myxoma or other cardiac tumors, moderate or severe mitral stenosis, recent myocardial infarction (\< 4 weeks), (EF) \< 30%, valve vegetations or infective endocarditis.
  • No other identified cause of stroke (such as arteritis, dissection, migraine, vasospasm, drug abuse, hypercoagulability, etc.)

Presence of LVD defined by at least one of the following criteria:

  • Moderately reduced left ventricular (LV) systolic function, defined as EF 30-49%.
  • LV wall motion abnormalities (LVWMAs), defined as hypokinetic, akinetic, or dyskinetic segments of the left ventricular wall not associated with recent or acute myocardial infarction (within 4 weeks).
  • LV aneurysm
  • Enlarged LV with or without spontaneous contrast
  • Non-compacted LV, with deep trabeculations or spongy LV
  • Cardiomyopathies, such as restrictive cardiomyopathy, hypertrophic cardiomyopathy, or cardiac amyloidosis

Patients capable of signing (IC) or, in the case of unconscious patients without an authorized legal representative, recruited in a "Deferred" mode

Exclusion criteria

Exclusion Criteria:

  • Major cardioembolic sources, as specified in the ESUS criteria Patients with a thrombophilic state secondary to active cancer, defined as "diagnosis of solid or hematologic malignant tumor within 6 months of stroke, ongoing oncological treatment, or hematologic cancer not in remission." Patients with ipsilateral carotid plaques to the ischemic stroke considered at high risk: thrombus on the wall, floating thrombus, ulcerated plaque.

Patients under 60 years of age with a high-risk patent foramen ovale (PFO) and stroke classified as "probable" PFO-associated stroke according to the PASCAL classification.

Pregnancy or puerperium. to MRI and CT with contrast agents

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (estimated)
Patient registry
No

Groups and cohorts

  • Embolic stroke of undetermined source with left ventricular disease

    Patients with embolic stroke of undetermined source and left ventricular disease, with no intracardiac thrombus identified on transthoracic echocardiography, will undergo advanced cardiac imaging such as cardiac MRI and/or CT

06

What researchers measure

Primary outcomes

  1. Prevalence of left ventricular thrombus on advanced cardiac imaging (CMRI and/or CCT)

    Prevalence of left ventricular thrombus detected by advanced cardiac imaging (CMR, CCT) compared with transthoracic echocardiography (TTE) in patients who underwent both investigations within 15 days of the index stroke

    Time frame: 15 days from the index stroke

Secondary outcomes

  1. Intracardiac thrombi detected by transthoracic echocardiography in all patients with ESUS and LVD. Recurrent ischemic stroke Systemic embolism Acute coronary events Major bleeding, defined by the International Society of Thrombosis and Hemostasis Mortal

    Incidence of major cardiovascular events (MACE) at 12 months

    Time frame: 12 months from the index stroke

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 36 months is below that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 23, 2025
StartActual
Sep 15, 2025
Primary completionEst.
Sep 15, 2028
CompletionEst.
Dec 31, 2028
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07298122
Lead sponsor
Niguarda Hospital
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Sep 15, 2025
Primary completion
Sep 15, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Dec 23, 2025

Study contacts

Angelo Cascio Rizzo, MD
Contact
angelo.casciorizzo@ospedaleniguarda.it
+390264442348
Angelo Cascio Rizzo, MD
principal investigator · ASST Grande Ospedale Metropolitano Niguarda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion